Ali Rajabi Zangi
1,2 
, Ali Azizi
3, Fatemeh Soltanmohammadi
1,2, Zohreh Asadi
4, Mohammad Sheibani
5,6*, Yousef Javadzadeh
2* 1 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Chemical Engineering, Faculty of Engineering, Arak University, Arak 38156-8-8349, Iran
5 Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
6 Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Abstract
Wafer drug delivery offers a promising approach to personalized medicine by enabling precise dosage adjustments, controlled release rates, and tailored drug responses. By carefully selecting the composition, wafers can optimize therapeutic outcomes for individual patients. The development of a wafer formulation involves choosing the appropriate active ingredients, excipients, and drug compounds, which directly impact stability, solubility, and release profile of the drug. This study addresses the essential components and characteristics required for formulating an optimized wafer product, alongside the critical control steps necessary for its evaluation. Additionally, the manufacturing process plays a key role in maintaining quality standards by ensuring consistent drug content, uniformity, and dissolution properties. Ultimately, thorough characterization and monitoring of wafer quality are vital to guarantee safety, efficacy, and stability. We begin by reviewing ongoing clinical trials and existing products currently available in the wafer market.